By Tess Stynes 

Pfizer Inc. plans to start U.S. shipments of biosimilar Inflectra, its copycat version of Johnson & Johnson's anti-inflammatory drug Remicade, at a 15% discount to Remicade's wholesale prices starting in late November.

Pfizer, which has U.S. commercialization rights to Inflectra, said the estimated wholesale price doesn't include discounts to payers, distributors and others.

Inflectra, developed by South Korea pharmaceutical company Celltrion Inc., received Food and Drug Administration approval earlier this year but faced legal challenges over a patent for Remicade.

Inflectra, the second approved biosimilar treatment in the U.S., is approved to treat rheumatoid arthritis, ulcerative colitis and Crohn's disease.

Write to Tess Stynes at tess.stynes@wsj.com

 

(END) Dow Jones Newswires

October 17, 2016 17:51 ET (21:51 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Pfizer Charts.